HOLISTA COLLTECH LIMITED — Capital/Financing Update 2025

Aug 25, 2025

==> picture [215 x 49] intentionally omitted <==

Holista Colltech Limited (ASX:HCT / ABN 24 094 515 992) 283 Rokeby Road Subiaco WA 6008 P: +61 412 474 180 W: www.holistaco.com

26 August 2025

BINDING SUPPLY AND DEVELOPMENT AGREEMENT WITH REGENEREX PHARMA, INC.

Holista Colltech Limited (ASX: HCT, “Holista” or “the Company”) is pleased to announce it has entered into a binding supply and development agreement (“the Agreement”) with Regenerex Pharma, Inc. (“Regenerex”, OTC-listed, USA), a U.S.based pharmaceutical company specialising in chronic wound healing solutions.

Under the Agreement, Holista will exclusively manufacture and supply its proprietary ovine collagen, including its patented 300 kDa intact collagen and nano-collagen technologies, for Regenerex’s use in the development, clinical testing, and global distribution of advanced wound care products. The initial commercial focus will be the United States, with expansion into other global markets to follow.

Key Terms of the Agreement

• Exclusivity: Regenerex has exclusive worldwide rights to market Holista’s collagen products for wound care applications.

• Minimum Purchase Commitments: Regenerex is required to purchase a minimum of USD50,000 in 2025, scaling to USD3 million in 2026, USD6 million in 2027, and USD9 million annually from 2028 onwards.

• Clinical Development: Regenerex will conduct and fund clinical studies and regulatory approvals with the U.S. FDA and other relevant authorities.

• Joint Innovation: Both companies will collaborate on new applications of nano-collagen in advanced wound care, with joint ownership of any resulting intellectual property.

• Manufacturing: Holista’s ovine collagen will be drawn down from stocks from its manufacturing facility in Collie (WA) and nano-collagen to be produced in Malaysia, under international GMP and halal certification standards.

• Termination: The agreement runs for the life of the relevant patents and may be terminated earlier, including for convenience on 90 days’ notice or for breach, insolvency or by mutual agreement.

Strategic Rationale

The Agreement aligns with Holista’s strategy to move up the collagen value chain into medical and pharmaceutical markets, building on recent developments in nanocollagen technology and partnerships. Regenerex’s expertise in chronic wound healing provides a strong pathway to commercialisation in the U.S.A., the largest wound care market globally.

1

Holista’s Managing Director, Mr Leong Man Loong, said: “This agreement with Regenerex represents a major milestone for Holista, securing a committed partner to take our collagen technologies into the global wound care market. The structure of the Agreement ensures minimum purchase commitments and strong growth potential, while leveraging Regenerex’s clinical expertise and U.S. market access.”

This announcement has been approved by the Directors of Holista Colltech Limited.

Ends

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, sciencedriven solutions that empower better living and create lasting value for our stakeholders worldwide.

2